The expression of PD-L1 in non-small cell lung cancer and its correlation with EGFR、ALK、KRAS gene mutation and its prognosis
Objective To investigate the expression of PD-L1 protein in non-small cell lung cancer(NSCLC),and to analyze the correlation between PD-L1 and EGFR,ALK,KRAS and the prognosis of NSCLC.Methods 164 patients who were diagnosed as NSCLC from January 2017 to April 2022 at the Department of pathology of the first division hospital of Xinjiang production and Construction Corps were collected retrospectively.The mutation status of EGFR,ALK and KRAS genes were detected by next generation sequencing,PD-L1 expression was detected by immunohistochemistry.Analyzing the correlation and prognosis of PD-L1 expression with EGFR,KRAS,and ALK genes in NSCLC patients.Results The expression of PD-L1 was no statistically significant differences in age,sex,smoking history,race,histological type and TNM staging(P＞0.05).According to the correlation analysis,PD-L1 expression was negatively correlated with EGFR gene mutation(R=-0.251,P＜0.01),positively correlated with ALK gene mutation(R=0.232,P＜0.01),and not correlated with BRAF gene mutation(R=-0.036,P＞0.05).Through one-year survival analysis,67.9％of patients with PD-L1 expression were positive and 84.1％were negative.Kaplan Meier Survival Analysis:Patients in the PD-L1 positive expression group were lower than those in the negative expression group(x2=4.505,P＜0.05).Conclusion PD-L1 expression is associated with tumor staging,EGFR,and ALK gene mutations in NSCLC patients,and PD-L1 negative expression has a longer survival period compared to positive expression.
NETL
NSTL
万方数据
